Evidence reviews, third-party testing, research-use labeling and the FDA.
· 24 min read
Which peptides U.S. compounding pharmacies can legally sell in 2026, how the 503A and 503B rules work, and what the April Category 2 removals and the July PCAC vote did and did not change.
· 25 min read
What RFK Jr. has actually done on peptides, what the FDA changed in 2026, the July PCAC vote results, and the full timeline through 2027, with primary sources.
· 7 min read
Learn what third-party testing for peptides actually verifies, what it doesn’t prove, and how to evaluate COAs and testing claims with confidence.
· 9 min read
Yes, peptide overdose is possible. See which peptides carry the most risk, how dosing errors happen, the symptoms to watch for, and when to seek care.
· 11 min read
Learn what "research only" means on peptide labels, why vendors use this language, and how to avoid common misunderstandings about compliance terminology.
· 12 min read
A research-backed breakdown of how GLP-1 receptor agonists affect the gallbladder and pancreas, including what the clinical data says about real-world risk.
· 23 min read
BPC-157 isn't FDA approved and was banned by WADA in 2022. What human pilot studies, 2025 reviews, and angiogenesis cancer concerns mean for safety decisions.
· 6 min read
Peptide Sciences shut down in early 2026. Here is what caused it, what it means for gray-market peptide access, and the vetted vendors still operating safely.
